Our free daily oncology focused e-news service.
Subscribe» | Search Archives»
(Novartis) May 17, 2013 - Results of a pivotal Phase III trial in women with HER2 positive (HER2+) advanced breast cancer showed that Afinitor (everolimus) tablets in combination with trastuzumab (Herceptin) and vinorelbine significantly extended progression-free survival (PFS) after prior therapy when compared to treatment with placebo plus trastuzumab and vinorelbine, meeting the study's primary endpoint.
read corporate press release »
(Bloomberg) May 20, 2013 - The U.K. is piloting a new genetic test developed by Illumina Inc. to help cancer patients and their doctors better identify appropriate treatments and help determine if relatives have cancer risk.
read article »
(Boston Globe) May 20, 2013 - Advances in genetic profiling have allowed doctors to match more of their cancer patients with treatments that will target their particular illnesses. But for some about one-third of cancer patients, there are no good matches, leaving them with only conventional chemotherapies and radiation.
read article (paid subscription required) »
News Story Commentary By Academic and Community Oncologists
Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.
OBR Job Board
Novocure has posted 3 new jobs and Sarah Cannon has 1 job posted on the OBR Job Board.